{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:19:08Z","timestamp":1787635148545,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-026-01511-0","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:29:42Z","timestamp":1787632182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging evidence gaps: the role of real-world data in tobacco harm reduction"],"prefix":"10.1186","volume":"23","author":[{"given":"Arielle","family":"Selya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gem","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venera","family":"Tomaselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-5721","authenticated-orcid":false,"given":"Riccardo","family":"Polosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"9","key":"1511_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015226.pub2","volume":"9","author":"N Lindson","year":"2023","unstructured":"Lindson N, Theodoulou A, Ordonez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023;9(9):015226. https:\/\/doi.org\/10.1002\/14651858.CD015226.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1511_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111090","volume":"27","author":"G Cohen","year":"2024","unstructured":"Cohen G, Bellanca CM, Bernardini R, Rose JE, Polosa R. Personalized and adaptive interventions for smoking cessation: emerging trends and determinants of efficacy. iScience. 2024;27(11):111090. https:\/\/doi.org\/10.1016\/j.isci.2024.111090.","journal-title":"iScience"},{"key":"1511_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev.publhealth.26.021304.144501","volume":"26","author":"KM Cummings","year":"2005","unstructured":"Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Ann Rev Public Health. 2005;26:583\u201399. https:\/\/doi.org\/10.1146\/annurev.publhealth.26.021304.144501.","journal-title":"Ann Rev Public Health"},{"issue":"1","key":"1511_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54962","volume":"8","author":"SE Jackson","year":"2025","unstructured":"Jackson SE, Brown J, Buss V, Shahab L. Prevalence of popular smoking cessation aids in England and associations with quit success. JAMA Netw Open. 2025;8(1):e2454962-e2454962. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54962.","journal-title":"JAMA Netw Open"},{"key":"1511_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-024-03847-6","author":"F Foxon","year":"2022","unstructured":"Foxon F, Niaura R. Use of nicotine products, prescription drug products, and other methods to stop smoking by US adults in the 2022 National Health Interview Survey. Intern Emerg Med. 2022. https:\/\/doi.org\/10.1007\/s11739-024-03847-6.","journal-title":"Intern Emerg Med"},{"key":"1511_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub5","author":"J Hartmann-Boyce","year":"2018","unstructured":"Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD000146.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1511_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub8","volume":"5","author":"J Livingstone-Banks","year":"2023","unstructured":"Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023;5(5):CD006103. https:\/\/doi.org\/10.1002\/14651858.CD006103.pub8.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1511_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/tobaccocontrol-2011-050129","volume":"22","author":"HR Alpert","year":"2013","unstructured":"Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control. 2013;22(1):32\u20137. https:\/\/doi.org\/10.1136\/tobaccocontrol-2011-050129.","journal-title":"Tob Control"},{"issue":"6","key":"1511_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jnci\/djx240","volume":"110","author":"EC Leas","year":"2018","unstructured":"Leas EC, Pierce JP, Benmarhnia T, White MM, Noble ML, Trinidad DR, et al. Effectiveness of pharmaceutical smoking cessation aids in a nationally representative cohort of American smokers. J Natl Cancer Inst. 2018;110(6):581\u20137. https:\/\/doi.org\/10.1093\/jnci\/djx240.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1511_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/tobaccocontrol-2015-052332","volume":"25","author":"SH Zhu","year":"2016","unstructured":"Zhu SH, Cummins SE, Gamst AC, Wong S, Ikeda T. Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers. Tob Control. 2016;25(4):464\u20139. https:\/\/doi.org\/10.1136\/tobaccocontrol-2015-052332.","journal-title":"Tob Control"},{"issue":"3","key":"1511_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00952990.2024.2439363","volume":"51","author":"S Shiffman","year":"2025","unstructured":"Shiffman S, Kim S, Goldenson NI, Sembower MA. Readiness to stop smoking and subsequent switching away to electronic nicotine delivery systems among adults who smoke cigarettes. Am J Drug Alcohol Abus. 2025;51(3):328\u201338. https:\/\/doi.org\/10.1080\/00952990.2024.2439363.","journal-title":"Am J Drug Alcohol Abus"},{"key":"1511_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107668","volume":"205","author":"N Kim","year":"2019","unstructured":"Kim N, McCarthy DE, Loh W-Y, et al. Predictors of adherence to nicotine replacement therapy: machine learning evidence that perceived need predicts medication use. Drug Alcohol Depend. 2019;205:107668. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107668.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1511_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/tc.2010.038703","volume":"20","author":"Y Le Strat","year":"2011","unstructured":"Le Strat Y, Rehm J, Le Foll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Tob Control. 2011;20(5):338\u201343.","journal-title":"Tob Control"},{"issue":"3","key":"1511_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0340668","volume":"21","author":"L Mazhar","year":"2026","unstructured":"Mazhar L, Krebs N, Allen SI, et al. Enhancing recruitment and retention strategies in human tobacco research. PLoS ONE. 2026;21(3):e0340668. https:\/\/doi.org\/10.1371\/journal.pone.0340668.","journal-title":"PLoS ONE"},{"issue":"5","key":"1511_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1360-0443.2007.01822.x","volume":"102","author":"J-F Etter","year":"2007","unstructured":"Etter J-F, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction. 2007;102(5):815\u201322. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01822.x.","journal-title":"Addiction"},{"key":"1511_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010216.pub10","author":"N Lindson","year":"2025","unstructured":"Lindson N, Livingstone-Banks J, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2025. https:\/\/doi.org\/10.1002\/14651858.CD010216.pub10.","journal-title":"Cochrane Database Syst Rev"},{"key":"1511_CR17","volume-title":"Social norms","author":"M Hechter","year":"2001","unstructured":"Hechter M, Opp KD. Social norms. Russell Sage Foundation; 2001."},{"issue":"21","key":"1511_CR18","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1056\/NEJMsa0706154","volume":"358","author":"NA Christakis","year":"2008","unstructured":"Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358(21):2249\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"1511_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S, Van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7(1):30.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1511_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1017\/s0033291720005127","volume":"51","author":"G Hammerton","year":"2021","unstructured":"Hammerton G, Munaf\u00f2 MR. Causal inference with observational data: the need for triangulation of evidence. Psychol Med. 2021;51(4):563\u201378. https:\/\/doi.org\/10.1017\/s0033291720005127.","journal-title":"Psychol Med"},{"key":"1511_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-024-03677-6","author":"S Kim","year":"2024","unstructured":"Kim S. New opportunities with ENDS for people who smoke and do not intend to quit smoking. Intern Emerg Med. 2024. https:\/\/doi.org\/10.1007\/s11739-024-03677-6.","journal-title":"Intern Emerg Med"},{"key":"1511_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102142","author":"MJ Carpenter","year":"2023","unstructured":"Carpenter MJ, Wahlquist AE, Dahne J, et al. Effect of unguided e-cigarette provision on uptake, use, and smoking cessation among adults who smoke in the USA: a naturalistic, randomised, controlled clinical trial. EClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102142.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"1511_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10826084.2024.2303990","volume":"59","author":"S Kim","year":"2024","unstructured":"Kim S, Shiffman S, Goldenson NI. Adult smokers\u2019 complete switching away from cigarettes at 6, 9, and 12 months after initially purchasing a JUUL e-cigarette. Subst Use Misuse. 2024;59(5):805\u201315. https:\/\/doi.org\/10.1080\/10826084.2024.2303990.","journal-title":"Subst Use Misuse"},{"key":"1511_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntae027","author":"KA Kasza","year":"2024","unstructured":"Kasza KA, Tang Z, Seo YS, et al. Divergence in cigarette discontinuation rates by use of electronic nicotine delivery systems (ENDS): longitudinal findings from the United States PATH study waves 1-6. Nicotine Tob Res. 2024. https:\/\/doi.org\/10.1093\/ntr\/ntae027.","journal-title":"Nicotine Tob Res"},{"issue":"12","key":"1511_CR25","doi-asserted-by":"publisher","first-page":"e2140880","DOI":"10.1001\/jamanetworkopen.2021.40880","volume":"4","author":"KA Kasza","year":"2021","unstructured":"Kasza KA, Edwards KC, Kimmel HL, et al. Association of e-cigarette use with discontinuation of cigarette smoking among adult smokers who were initially never planning to quit. JAMA Netw Open. 2021;4(12):e2140880. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.40880.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1511_CR26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.amepre.2022.12.008","volume":"64","author":"S Trigger","year":"2023","unstructured":"Trigger S, Xu X, Malarcher A, Salazar E, Shin H, Babb S. Trends in over-the-counter nicotine replacement therapy sales, U.S., 2017\u20122020. Am J Prev Med. 2023;64(5):650\u20137. https:\/\/doi.org\/10.1016\/j.amepre.2022.12.008.","journal-title":"Am J Prev Med"},{"key":"1511_CR27","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7225a1","author":"FRM Ali","year":"2020","unstructured":"Ali FRM, Seidenberg AB, Crane E, Seaman E, Tynan MA, Marynak K. E-cigarette unit sales by product and flavor type, and top-selling brands, United States, 2020\u20132022. MMWR Morb Mortal Wkly Rep. 2020. https:\/\/doi.org\/10.15585\/mmwr.mm7225a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1511_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13032-z","volume":"22","author":"M Lund","year":"2022","unstructured":"Lund M, Lund I. Smoking cessation aids and strategies: a population-based survey of former and current smokers in Norway. BMC Public Health. 2022;22(1):631. https:\/\/doi.org\/10.1186\/s12889-022-13032-z.","journal-title":"BMC Public Health"},{"issue":"1","key":"1511_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-8-19","volume":"8","author":"B Rodu","year":"2011","unstructured":"Rodu B. The scientific foundation for tobacco harm reduction, 2006-2011. Harm Reduct J. 2011;8(1):19. https:\/\/doi.org\/10.1186\/1477-7517-8-19.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1511_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11739-025-04237-2","volume":"21","author":"R Polosa","year":"2026","unstructured":"Polosa R, Fagerstrom K, Rodu B. The emerging role of oral nicotine pouches in tobacco harm reduction. Intern Emerg Med. 2026;21(3):799\u2013804. https:\/\/doi.org\/10.1007\/s11739-025-04237-2.","journal-title":"Intern Emerg Med"},{"key":"1511_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph13111110","author":"L Ramstr\u00f6m","year":"2016","unstructured":"Ramstr\u00f6m L, Borland R, Wikmans T. Patterns of smoking and snus use in Sweden: implications for public health. Int J Environ Res Public Health. 2016. https:\/\/doi.org\/10.3390\/ijerph13111110.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"1511_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/tc.2005.014969","volume":"15","author":"LM Ramstr\u00f6m","year":"2006","unstructured":"Ramstr\u00f6m LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control. 2006;15(3):210\u20134. https:\/\/doi.org\/10.1136\/tc.2005.014969.","journal-title":"Tob Control"},{"issue":"1","key":"1511_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.healthpol.2007.08.006","volume":"86","author":"S Shiffman","year":"2008","unstructured":"Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86(1):17\u201326. https:\/\/doi.org\/10.1016\/j.healthpol.2007.08.006.","journal-title":"Health Policy"},{"key":"1511_CR34","unstructured":"Food and Drug Administration (FDA) Center for Tobacco Products (CTP). Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications \u2013 Considerations Related to Youth Risk. 2026. Draft Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/flavored-electronic-nicotine-delivery-systems-ends-premarket-applications-considerations-related."},{"key":"1511_CR35","unstructured":"FDA and NIH Award Funding for New Center for Rapid Surveillance of Tobacco. 2023. https:\/\/www.fda.gov\/tobacco-products\/ctp-newsroom\/fda-and-nih-award-funding-new-center-rapid-surveillance-tobacco."},{"key":"1511_CR36","unstructured":"US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA\u2019s new strategic framework to advance use of real-world evidence to support development of drugs and biologics. Updated December 6, 2018. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm627760.htm."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01511-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:29:43Z","timestamp":1787632183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01511-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01511-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AS is an employee of Pinney Associates, Inc. Since October 2019, Pinney Associates has been and continues to consult to Juul Labs on nicotine vapor products to advance tobacco harm reduction. JLI partly funded AS\u2019s effort in the preparation of this manuscript and provided comments on a near-final draft. AS also consults to the Global Forum on Nicotine (GFN). In addition, in the past 3\u00a0years, Pinney Associates has consulted to Philip Morris International (PMI) solely on US regulatory pathways for non-combustible, non-tobacco, nicotine products. PA does not consult on combustible tobacco products. Also in the past 3\u00a0years, AS individually provided consulting services on behavioral science to the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) through ECLAT Srl., which received funding from the Foundation for a Smokefree World (FSFW; now the Global Action to End Smoking (GA). Neither FSFW\/GA, GFN, nor PMI had any role in, or oversight, of this study. GL is employed by Juul Labs, Inc. (JLI). JLI provided comments on a near-final version of this manuscript. RP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. He has received grants from U-BIOPRED and AIR-PROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Global Action to End Smoking, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A\/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl. (Independent nicotine company), JUUL Labs (Independent nicotine company), Duska Therapeutics, Forest Laboratories, Ministero dell'Universita\u2019 e della Ricerca (MUR) PNRR 3277\/2021 (CUP E63C22000900006), PNRR 341\/2022 (CUP E63C22002080006), and PNRR TNE23-00019 (CUP H71I24000300002), funded by NextGenerationEU of the European Union (EU), and the ministerial grant PON REACT-EU 2021 GREEN- Bando 3411\/2021 by Ministero dell Universita' and (MUR) \u2013 PNRR EU Community. He is founder of the Center for Tobacco Prevention and Treatment (CPCT) at the University of Catania and of the Center of Excellence for the Acceleration of Harm Reduction at the same university. He receives consultancy fees from Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbooks royalties from Elsevier. He is also involved in a patent application for ECLAT Srl. He is a pro bono scientific advisor for Lega Italiana Anti Fumo (LIAF) and the International Network of Nicotine Consumers Organizations (INNCO); and he is Chair of the European Technical Committee for Standardization on \u201cRequirements and test methods for emissions of electronic cigarettes\u201d (CEN\/TC 437; WG4); and scientific advisor\u00a0of the non-profit Foundation RIDE2Med. VT is associate professor of Social Statistics at the University of Catania (Italy). She declares no conflict of interest.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"140"}}